tbuckley/cabot-search huggingface dataset:
MTR-11MicroRNA TARGETING MGMT PROLONGS PROGNOSIS WITH GBM IN VIVO
Authors: Daisuke Ogawa, Shijie Hu, Masaki Okada, Keisuke Miyake, Takashi Tamiya, E.A. Chiocca, Jakub Godlewski
Journal: Neuro-Oncology (2015)

It is well known that O6-methylguanine-DNA methyltransferase (MGMT) is related to resistance of aggressive brain tumor glioblastoma (GBM) to DNA alkylating agent Temozolomide (TMZ) therapy. In this study, we searched for microRNA that regulate MGMT expression and give better sensitivity to TMZ. We picked up 6 microRNAs out of tens of candidates from several binding site prediction software, which have complementary seed region with 3'-UTR of MGMT messenger RNA (mRNA). One out of 6 microRNAs down regulated MGMT mRNA and protein more than 40% in both T98G glioma cell line and primary GBM cell line (GBM30). Direct interaction between miR-655 and 3’-UTR of MGMT mRNA was confirmed by luciferase reporter assay. Sensitivity to TMZ was increased in microRNA transfected T98G cells as same level as U87MG which cell line is not expressing MGMT and the T98G cells down regulated MGMT by siRNA. We will also show that GBM30 expressing microRNA transplanted in nude mice survived better than control with injection of TMZ in vivo. Thus, this microRNA has endogenous mechanism that increase chemo-sensitivity to TMZ by suppressing drug resistance gene MGMT. Further study of microRNA effecting cell proliferation and survival related to TMZ will be discussed. This study will provide a new target to enhance efficacy of chemotherapy.
A Novel Approach for Analyzing Gene Expression Profiles Defines Two Distinct Subgroups of t(4;11) Positive Infant Acute Lymphoblastic Leukemia Patients.
Authors: Ronald W. Stam, Stefan Bohlander, Renate Kirschner-Schwabe, Susan Arentsen-Peters, Rob Pieters, Theo Dingermann, Rolf Marschalek
Journal: Blood (2007)
Persistent Opioid Use After Major Surgery—Reply
Authors: Neilesh Soneji, Hance A. Clarke, Duminda N. Wijeysundera
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Convergent evidence for top-down effects from the “predictive brain”
Authors: Claire O'Callaghan, Kestutis Kveraga, James M. Shine, Reginald B. Adams, Moshe Bar
Journal: Behavioral and Brain Sciences (2016)

Abstract Modern conceptions of brain function consider the brain as a “predictive organ,” where learned regularities about the world are utilised to facilitate perception of incoming sensory input. Critically, this process hinges on a role for cognitive penetrability. We review a mechanism to explain this process and expand our previous proposals of cognitive penetrability in visual recognition to social vision and visual hallucinations.
Peptides Binding to Kunitz Domain 1 of Tissue Factor Pathway Inhibitor (TFPI) Inhibit All Functions of TFPI and Improve Thrombin Generation of Hemophilia Plasma
Authors: Michael Dockal, Johannes Brandstetter, Martin Ludwiczek, Georg Kontaxis, Markus Fries, M C L G D Thomassen, A Heinzmann, Hartmut J. Ehrlich, Katerina Prohaska, Rudolf Hartmann, Jan Rosing, Friedrich Scheiflinger
Journal: Blood (2011)
Targeting the Hedgehog Signaling Pathway in Therapy-Resistant BCR-ABL1 Positive Leukemia with Ponatinib
Authors: Seiichiro Katagiri, Tetsuzo Tauchi, Seiichi Okabe, Eishi Ashihara, Shinya Kimura, Taira Maekawa, Kazuma Ohyashiki
Journal: Blood (2011)
Impact of Baseline Free Light Chain Ratio (rFLC) On Clinical Outcomes and Change in rFLC During Treatment in Patients with Relapsed/Refractory Multiple Myeloma Treated with Pegylated Liposomal Doxorubicin Plus Bortezomib or Bortezomib Alone.
Authors: Valeria Magarotto, Anil Londhe, Keith C. Lantz, Colin Lowery, Pieter Sonneveld, Joan Bladé, Jean-Luc Harousseau, Robert Z. Orlowski
Journal: Blood (2009)
Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update
Authors: H. Jean Khoury, Carlo Gambacorti-Passerini, Hagop M. Kantarjian, Dong-Wook Kim, David Marin, Pedro E Dorlhiac-Llacer, Andrey Zaritskey, Juan Navarro, Eduardo O Bullorsky, Sarit Assouline, Eric Leip, Virginia Kelly, Kathleen Turnbull, Nadine Besson, Jorge E Cortes
Journal: Blood (2012)
Halofuginone Exerts Antiproliferative and Antiangiogenic Actions on Acute Promyelocytic Leukemia Cells through Modulation of the TGFβ Pathway.
Authors: Lorena L. Figueiredo-Pontes, Ana Silvia G. Lima, Barbara A. Santana-Lemos, Ana Paula A. Lange, Luciana C. Oliveira, Aglair B. Garcia, Marcia S. Baggio, Amelia A. Goes, Rodrigo A. Panepucci, Marco A. Zago, Arnon Nagler, Roberto P. Falcao, Eduardo M. Rego
Journal: Blood (2007)
MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors
Authors: Jorge Torres-Ferreira, João Ramalho-Carvalho, Antonio Gomez, Francisco Duarte Menezes, Rui Freitas, Jorge Oliveira, Luís Antunes, Maria José Bento, Manel Esteller, Rui Henrique, Carmen Jerónimo
Journal: Molecular Cancer (2017)

Contemporary challenges of prostate cancer (PCa) include overdiagnosis and overtreatment, entailing the need for novel clinical tools to improve risk stratification and therapy selection. PCa diagnosis and prognostication might be perfected using epigenetic biomarkers, among which aberrant DNA methylation of microRNA promoters has not been systematically explored. Herein, we identified aberrantly methylated microRNAs promoters in PCa and assessed its diagnostic and prognostic biomarker potential. Using HumanMethylation450 BeadChip-based analysis differentially methylated CpGs in microRNA promoters were identified. Promoter methylation of six microRNAs (miR-34b/c, miR-129-2, miR-152, miR-193b, miR-663a and miR-1258) was analyzed by qMSP in three sets (180 prostatectomies, 95 urine sediments and 74 prostate biopsies). Biomarkers' diagnostic (validity estimates) and prognostic [disease-free (DFS) and disease-specific survival (DSS)] performance was assessed. Significantly higher promoter methylation levels in PCa were confirmed for six candidate microRNAs. Except for miR-152, all displayed AUC values higher than 0.90, with miR-1258 and miR-193b disclosing the best performance (AUC = 0.99 and AUC = 0.96, respectively). In urine samples, miR-193b showed the best performance (91.6% sensitivity, 95.7% specificity, AUC = 0.96). Moreover, higher miR-129-2 independently predicted for shorter DSS and miR−34b/c methylation levels independently predicted for shorter DFS and DSS. Quantitative miR-193b, miR-129-2 and miR-34b/c promoter methylation might be clinically useful PCa biomarkers for non-invasive detection/diagnosis and prognostication, both in tissue and urine samples.
NIMG-52DYNAMIC CONTRAST ENHANCED MR ESTIMATION OF PHARMACOKINETIC PARAMETERS OF GLIOBLASTOMA MULTIFORME TUMORS: A COMPARISON STUDY FOR PERITUMORAL AND GLOBAL ARTERIAL INPUT FUNCTIONS USING MODEL SELECTION TECHNIQUE
Authors: Azimeh N.V. Dehkordi, Alireza Kamali-Asl, Brent Griffith, Tom Mikkelsen, Ali S. Arbab, Lisa Scarpace, Hamid Soltanian-Zadeh, Milan V. Pantelic, David S. Nathanson, Hassan Bagher-Ebadian
Journal: Neuro-Oncology (2015)

Identification of Arterial Input Function (AIF) is one of the crucial steps for quantitative analysis of tissue vascular permeability in Dynamic Contrast Enhanced Magnetic Resonance Imaging studies. In practice, the global AIF is usually identified by experts, which never accounts for dispersion, delay, and partial volume effects. In this pilot study, it is hypothesized that embedded tumors are supplied by their surrounding tissue. This study compares the MR estimates of Pharmacokinetic parameters (PK) in Glioblastoma-Multiforme (GBM) tumors for Peritumoral-derived AIF (PTAIF) as opposed to the use of global AIF. Using the trace of the contrast agent concentration (∝ to relaxivity change, ΔR1) in seventeen treatment-naive GBM patients, a neuroradiologist manually picked the global AIF for each patient. A series of two-dimensional Region of Interests were drawn on the periphery of each tumor in each slice to generate a three-dimensional ROI for encompassing the whole tumor. Then the ΔR1 profile was averaged over the 3D-ROI to generate the PTAIF. For each patient, the global AIF and PTAIF profiles were normalized to the brain white matter. Using the Model-Selection technique and Maximum-Likelihood algorithm, all PK parameters of three Toft-derived models (models 1, 2 and 3), were estimated for two AIFs. The results revealed that PK analysis using PTAIF generates higher plasma volumes in model-1 and model-2 (20% and 60%) with 52% lower plasma volume in model-3 compared to global AIF. PK analysis using PTAIF generates lower transfer constants in models-2 and 3 (54% and 90% for outward-transfer-constant of model-2 and 3 respectively and 13% for backward-transfer-constant of model-3). Also, the extra-vascular-extra-cellular space estimated by the PTAIF compared to the AIF shows significant reduction. The results of this study imply that using Tissue Input Function such as PTAIF compared to the globally selected AIF may highly change the estimates of the PK parameters.
B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell- Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo
Authors: Emily M. McWilliams, Carolyn Cheney, Jeffrey A. Jones, Joseph M. M. Flynn, Kami Maddocks, Leslie A. Andritsos, Heather Huet, Hermann Gram, Johan Baeck, Natarajan Muthusamy, John C. Byrd
Journal: Blood (2013)
DDEL-17CSF PHARMACOKINETICS AND PHARMACODYNAMICS IN BRAIN CANCER PATIENTS ON HIGH-DOSE ERLOTINIB
Authors: Sandeep Pingle, Emma Langley, Tiffany Juarez, Marlon Saria, Gary Meyer, Phillip Kim, Santosh Kesari
Journal: Neuro-Oncology (2015)

Failure of brain cancer patients to respond to traditional doses of small molecule inhibitors necessitates a change in the treatment paradigm. We hypothesize that alternate high-dose pulsatile regimens would effectively target brain tumors in such patients. Here, we present the pharmacokinetic and pharmacodynamic effects of high-dose erlotinib in patients with primary glioma or metastatic NSCLC patients. Among the five patients examined, erlotinib concentrations reached up to 131nM in the cerebrospinal fluid (CSF), when high-dose erlotinib was administered at 600 to 1200 mg every four to six days. Additionally, CSF drug clearance was decreased, with an increased dosing regimen in one of the patients. In one patient, the area under the curve (AUC) estimations increased by 24% for the CSF, but only 2% increase for the plasma, following an increase in dose from 150 mg to 600 mg of erlotinib. Importantly, increasing CSF concentrations of erlotinib directly correlated with effects on kinase activity in tumor cells from the CSF. Thus, our data indicate that high-dose pulsatile erlotinib improves its CSF pharmacokinetics; moreover, this regimen is associated with a corresponding pharmacodynamic effect on tumors. Our approach may overcome the blood-brain barrier, and prove transformative for the treatment of patients with primary and metastatic brain cancers.
In Vitro and In Vivo Sensitization of Malignant Cells to Autologous Natural Killer Cell Cytotoxicity Following Exposure to Bortezomib.
Authors: Andreas Lundqvist, Kristy Greeneltch, Maria Berg, Shivani Srivastava, Nanae Harashima, Hisayuki Yokoyama, Aleah Smith, Scott Abrams, Richard Childs
Journal: Blood (2006)
Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia
Authors: Jae H Park, Stephen S. Chung, Benjamin Durham, Young Rock Chung, Sasinya Scott, Bartlomiej Getta, Eunhee Kim, Alan Saven, Richard M. Stone, Kanti R Rai, Michael R. Grever, Jessica K. Altman, Neal Rosen, Ross L. Levine, Michael Berger, Martin S Tallman, Omar Abdel-Wahab
Journal: Blood (2015)
Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical Features
Authors: Massimo Breccia, Paola Finsinger, Roberto Latagliata, Laura Cannella, Giuseppina Loglisci, Mauro Nanni, Michelina Santopietro, Adriano Salaroli, Agostino Tafuri, Giuliana Alimena
Journal: Blood (2010)
Hereditary diffuse gastric cancer (HDGC): Clinical characteristics of a prospective cohort
Authors: M. A. Shah, E. Sheehy, M. Harlan, J. Randazzo, R. J. Perera, K. Pascarelli, M. M. Kemeny, D. Schrag, D. G. Coit, D. P. Kelsen
Journal: Journal of Clinical Oncology (2008)

4525 Background: HDGC is an autosomal dominant cancer syndrome associated with early onset diffuse GC. Germline mutations in E-cadherin (CDH1) are responsible for the disease but are identified in only 20–30% of patients who meet clinical criteria. We began a prospective multicenter GC registry to capture epidemiologic and family history data matched with DNA and tissue to characterize phenotypic and risk factor profiles and their associations with HDGC and other non-HDGC hereditable GC. Herein, we report the clinical characteristics of HDGC. Methods: All patients with GC are eligible for registry participation. HDGC criteria: diffuse GC (< age 45), diffuse GC (< age 50) with 1 relative with GC, diffuse GC (any age) with 2 or more relatives with GC, or a personal or family history of diffuse GC with lobular breast cancer or signet ring colon cancer. Non-HDGC high risk pts: diagnosed < age 50 or with a family history of GC(at least one 1st degree or two 2nd degree relatives with GC), but do not meet HDGC criteria. Sporadic GC: diagnosed > age 50, without family history. Participants complete a GC risk factor questionnaire, family history, and provide blood and tissue for repository. Results: 203 patients have enrolled since Jan 2006. GC risk factor questionnaires are available from 149 patients(76%), see table. CDH1 mutations have been identified in 5 families(15%) who meet HDGC criteria. All mutations have been previously reported including 377delC, 2276delG, 2287G ⟶T, and 2398delC. Prophylactic gastrectomies in CDH1 mutation carriers have been performed in 7 pts, each without major complications. Numerous SNPs in CDH1 have been identified. Risk factors for GC including tobacco, salt use, and H pylori were similar between groups. Conclusions: Except for age and histology, the demographic breakdown and risk factor assessments of HDGC pts is similar to other non HGGC high genetic risk pts and to pts with sporadic GC. The GC registry will expand to international sites. Supported by the DeGregorio Family Foundation and the Byrne Foundation Demographic and Risk Factor Assessment Demographics (N = 203) HDGC (n=42) Non-HDGC high risk (n=78) Sporadic (n=83) Age at Diagnosis 45 (29–69) 52 (21–88) 67 (50–91) Race White 62% White 64% White 65% Hispanic 14% Hispanic 14% Hispanic 14% Asian 14% Asian 14% Asian 12% Black 7% Black 9% Black 14% Risk Factors HDGC (n=34) Non-HDGC high risk (n=59) Sporadic (n=56) Ever Smoked 53% 56% 57% Daily use of table salt 41% 47% 36% H pylori infection (self-report) 24% 10% 9% No significant financial relationships to disclose.
Ficolin-1 Is Present in a Highly Mobilizable Subset of Human Neutrophil Granules and Associates with the Cell Surface after Stimulation with fMLP.
Authors: Sara Roervig, Christian Honore, Lars-Inge Larsson, Sophie Ohlsson, Corinna cavan Pedersen, Lars Christian Jacobsen, Jack B. Cowland, Peter Garred, Niels Borregaard
Journal: Blood (2008)
Cytogenetic Risk Features in MDS-Update and Present State.
Authors: Julie Schanz, Heinz Tuechler, Francesc Solé, Mar Mallo, Barbara Hildebrandt, Marilyn L. Slovak, Kazuma Ohyashiki, Christian Steidl, Christa Fonatsch, Michael Pfeilstoecker, Thomas Noesslinger, Peter Valent, Aristoteles Giagounidis, Michael Luebbert, Reinhard Stauder, Otto Krieger, Michelle M. Le Beau, John M Bennett, Peter L Greenberg, Ulrich Germing, Detlef Haase
Journal: Blood (2009)
Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries
Authors: Claude Negrier, Lynda Mae Lepatan, Faralzah Karim, Anne Lienhart, Denise Wolko, Christine Voigt, Iris C. Jacobs, Elena Santagostino
Journal: Blood (2015)
NIMG-05IDENTIFICATION OF IMAGING SIGNATURES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III (EGFRvIII) IN GLIOBLASTOMA
Authors: Spyridon Bakas, Hamed Akbari, Jared Pisapia, Martin Rozycki, Donald M. O'Rourke, Christos Davatzikos
Journal: Neuro-Oncology (2015)

Glioblastoma (GBM) is the most common and aggressive adult brain tumor, with 14 months average survival. Epidermal growth factor receptor variant III (EGFRvIII) mutation is an important factor in driving tumor progression and defining prognosis in GBM patients, hence evidence of its presence can affect treatment decisions. The aim of this study is to identify quantitative imaging signatures of EGFRvIII. We used preoperative multi-parametric (T1-Gad, T2-FLAIR, Dynamic-Susceptibility-Contrast) magnetic resonance imaging data from a retrospective cohort of 64 patients (42 EGFRvIII-negative) with de novo GBM. We hypothesized that EGFRvIII-positive tumors, the more aggressive subtype, have a uniformly dense distribution of tumor cells throughout the peritumoral edematous region, as opposed to EGFRvIII-negative tumors, where tumor cell burden decreases farther from the tumor. To assess this peritumoral heterogeneity, we defined one region of interest (ROI) adjacent to the tumor and another at the farthest from the tumor but still within the edematous tissue. Perfusion temporal dynamics of each ROI were summarized via principal component analysis. The Bhattacharyya coefficient was used as a measure of separability (range [0,1]) between the dynamics of the two ROIs, for each patient. Values close to 0 indicate similar perfusion dynamics between the ROIs, which is consistent with uniformly and aggressively infiltrating tumors. Conversely, values close to 1 indicate substantial difference between the two ROIs, which would be consistent with less infiltrative tumors. The distributions of these separability measurements between EGFRvIII-negative and EGFRvIII-positive patients were very highly separable, with median values of 0.48 (Interquartile range: 0.251-0.647) and 0.209 (Interquartile range: 0.064-0.309), respectively. A two-tailed paired t-test confirmed the statistical significance of the results (p-value = 0.00007). These results suggest that discrimination of the EGFRvIII mutation status, which is critical for personalized treatment decisions and response evaluation, can be achieved based solely on assessing the peritumoral heterogeneity on in vivo imaging data.
“What have we GANEd?” A theoretical construct to explain experimental evidence for noradrenergic regulation of sensory signal processing
Authors: Rachel Navarra, Barry Waterhouse
Journal: Behavioral and Brain Sciences (2016)

Abstract The GANE (glutamate amplifies noradrenergic effects) theory posits a mechanism for amplifying noradrenergic modulatory actions and enhancing the processing of high-priority sensory signals for immediate or future experience-guided action. This theoretical construct is thought provoking with respect to the central processing of high-priority versus low-priority stimuli, but it requires some refinement to account for physiological fluctuations in NE efflux as a function of naturally occurring transitions in behavioral state and the experimentally observed phenomena associated with noradrenergic regulation of sensory signal transfer.
A phase I trial of IMC A12 and temsirolimus in children with refractory solid tumors: A Children’s Oncology Group study.
Authors: Maryam Fouladi, John Peter Perentesis, Lars M. Wagner, Ashish M Ingle, George Thomas, Darcy A. Krueger, Peter Houghton, A.A. Vinks, L. Austin Doyle, Brenda Weigel, Susan Blaney
Journal: Journal of Clinical Oncology (2012)

9541 Background: IMC-A12, a fully recombinant IgG1 monoclonal antibody that targets the human IGF-IR and inhibits downstream signaling of MAPK and PI3K/AKT, and temsirolimus, an mTOR inhibitor, have demonstrated preclinical single agent, antitumor activity against many pediatric tumors. A phase I and pharmacokinetic (PK) trial evaluating the combination of these agents was conducted in children with refractory solid and CNS tumors. Methods: Using a modified 3+3 design, IMC-A12 and temsirolimus were administered intravenously once every 7 days in 28 day cycles. Serial PK studies were obtained on day 1, cycle 1 and trough samples were obtained on days 15 and 28. Biology studies included assessment of IGFR and insulin receptor expression and phosphorylation in archival tumor samples and phosphorylation of IGFR and mTOR downstream targets in peripheral blood mononuclear cells (PBMC) pre and post therapy. Results: Thirty-nine patients [20 male, median age 11.8 years (range 1-21.5)] with rhabdomyosarcoma (n=10), osteosarcoma (n=6), Ewings sarcoma (n=5), astrocytoma (n=5), or other tumors (n=13) were enrolled; 33 were evaluable for toxicity. At dose level 1 [IMC-A12 (6 mg/kg); temsirolimus (15 mg/m 2 )], 2 DLTs (grade 3 hypercholestrolemia, mucositis) occurred among 6 evaluable patients. Six more patients were accrued and 3 additional DLTs were observed (grade 3 ALT, fatigue and prolonged thrombocytopenia &gt; 14 days). At dose level 0 [IMC-A12 (6 mg/kg); temsirolimus (10 mg/m 2 )], dose-limiting mucositis occured in 2/6 patients. At dose level -1 [IMC-A12, (4 mg/kg) and temsirolimus at (8 mg/m 2 )], 0 of 3 patients experienced a DLT. At an intermediate dose level [IMC-A12 (6 mg/kg) and temsirolimus (8 mg/m 2 )], 1 of 6 patients experienced mucositis; among an expanded PK cohort for children &lt;12 years, none of 6 patients experienced a DLT. Target inhibition (decreased S6K1 and PAkt) in PBMCS were noted at all dose levels. At 8 mg/m 2 , the median sirolimus AUC was 225 μg/ml · h (159-226), and median temsirolimus AUC was 3340 μg/ml · h (1894-4387), and median Cmax 1176 μg/ml (480-2231). Conclusions: The recommended pediatric phase II doses for the combination of IMC-A12 and temsorolimus are 6 mg/kg and 8 mg/m 2 , respectively.
Cancer-Testis Antigen MAGE-C2/CT10 Promotes Proliferation and Enhances Resistance to p53 Mediated Apoptosis in Multiple Myeloma
Authors: Nesrine Lajmi, Julia Templin, Sara Yousef, Tim Luetkens, Stefanie Spock, York Hildebrandt, Katrin Bartels, Yanran Cao, Carsten Bokemeyer, Nicolaus Kröger, Djordje Atanackovic
Journal: Blood (2012)
The VIP-ABVD Regimen Is Not Superior to the CHOP 21 for the Treatment of Non Epidermotropic Peripheral T Cell Lymphoma. Final Results of the “LTP95” Protocol of the GOELAMS.
Authors: Remy Gressin, Michel Peoch, Eric Deconinck, Philippe Casassus, Bernard Desablens, Delphine Senecal, Philippe Quitet, Jean Pierre Vilque, Charles Foussard, Houchingue Eghbali, Jerome Jaubert, Olivier Tournilhac, Virginie Lucas, Vincent Delwail, Bachera Choufi, Antoine Thyss, Francoise Huguet, Frederic Maloisel, Bruno Richard, Noel-Jean Milpied, Philippe Colombat
Journal: Blood (2006)